Cocrystal Pharma Q3 net loss $4.2M ($0.41/sh) vs $5.7M loss year ago; cash $29.7M

Cocrystal Pharma, Inc.

2023-Q3 EPS reported -$1.43

Net loss for Q3 2023 was $4.2M ($0.41 per share) compared with net loss of $5.7M ($0.70 per share) in Q3 2022.
R&D expenses increased to $4.2M from $3.9M, driven by clinical advancement of CC-42344 and CDI-988 trials.
Cash and equivalents $29.7M as of Sep 30, 2023, down from $37.1M at Dec 31, 2022; working capital $30.3M.
Enrollment underway in Phase 1 trial for dual coronavirus-norovirus oral protease inhibitor CDI-988.
Phase 2a human challenge trial for oral influenza A drug CC-42344 expected to begin dosing before year-end 2023; inhaled CC-42344 Phase 1 planned H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cocrystal Pharma, Inc. reported financial results for three and nine months ended September 30, 2023.

Period: three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Cocrystal Pharma, Inc. (the "Company") issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040327

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.